Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

An Important Medical Advance – The First FDA-Approved Ebola Vaccine Announced!

An Important Medical Advance – The First FDA-Approved Ebola Vaccine Announced!

Ebola virus disease (EVD), Ebola hemorrhagic fever, or Ebola, caused by Ebola virus, is rare but severe and often fatal, respecting no borders. It spreads through direct contact with infected wild animals' or people's blood, fluids, and tissues, or contaminated surfaces such as bedding and clothing. Sudden symptoms may include fever, fatigue, muscle pain, headache, and sore throat, followed by vomiting, diarrhea, rash, kidney and liver dysfunction, and sometimes internal and external bleeding. Incubation ranges from 2 to 21 days. Caregivers, including workers not using appropriate infection control, face highest risk. Vaccination is therefore essential to prevent outbreaks and stop spread. On 19 December 2019, FDA (the US Food and Drug Administration) announced Ervebo, the first approved vaccine preventing Ebola in people aged 18 and older. It targets the Zaire species of Ebolavirus. Below Is the Biological Classification:

• Group: Group V (-) ssRNA

• Order: Mononegavirales

• Family: Filoviridae

• Genus: Ebolavirus

• Species: Zaire ebolavirus (EBOV), Sudan ebolavirus(SUDV), Reston ebolavirus (RESTV), Tai forest ebolavirus (TAFV), Bundibugyo ebolavirus (BDBV). US cases are very rare, resulting from infections acquired abroad by travelers or health workers treating patients. Outbreaks were first documented in the 1970s in sub-Saharan Africa. From 2014 to 2016, Guinea, Liberia, and Sierra Leone saw over 28.000 cases and over 11.000 Zaire ebolavirus deaths. The Democratic Republic of Congo currently faces the second-largest outbreak. In 2018, WHO and Congo began investigational Ervebo under expanded access. Approval is supported by a study in people aged 18-20 and older during the 2014-2016 Guinea outbreak. Individuals with laboratory-confirmed disease (3.537 people) were evaluated with “immediate” or 21-day “delayed” vaccination. Comparing 2.108 immediate with 1.429 delayed recipients, for cases with symptom onset 10 days after vaccination, Ervebo was % 100 effective . Safety was assessed in approximately 15.000 people in Africa, Europe, and North America. Common effects were injection pain, swelling, redness, headache, fever, joint-muscle pain, and fatigue. Ervebo is a single-injection live attenuated vaccine genetically engineered to contain a Zaire ebolavirus protein. FDA prioritized its development and evaluation because of public health importance, working closely with the company and completing safety and efficacy assessment in under six months.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

An Important Medical Advance – The First FDA-Approved Ebola Vaccine Announced!

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy